Peptide Profile
Vesugen
Lys-Glu-Asp · Vascular bioregulator · Khavinson vascular peptide
Vesugen is a synthetic peptide classified as a Khavinson-class bioregulator targeted at vascular endothelial and smooth muscle tissue, investigated for cytoprotective and anti-aging effects on the vascular wall through proposed…
- Half-life
- Unknown
- Routes
- subcutaneous, oral
Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.
Educational research tools — not medical advice.
What Vesugen is
About Vesugen
Tripeptide bioregulator targeting vascular endothelium; normalizes gene expression in smooth muscle and endothelial cells; reduces lipid accumulation in vessel walls
Vesugen is a synthetic peptide classified as a Khavinson-class bioregulator targeted at vascular endothelial and smooth muscle tissue, investigated for cytoprotective and anti-aging effects on the vascular wall through proposed gene expression regulatory mechanisms acting on endothelial and smooth muscle cell populations. Like other Khavinson bioregulator peptides, vesugen is proposed to modulate gene expression in target vascular cells through interactions with chromatin regulatory elements and transcription factor binding sites, with effects proposed to support endothelial integrity and vascular wall homeostasis under conditions of aging-related cellular stress. Published research on Khavinson-class short peptides has characterized systematic gene expression regulatory effects and cell differentiation regulatory capacity across multiple tissue types, providing the class-level mechanistic framework within which vesugen's vascular effects are proposed. Vesugen has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives entirely from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals.
Vesugen Benefits & Research Areas
Research Signals
Population research notes
These signals reflect research interest areas, not treatment indications.
What the evidence says about Vesugen
Research Evidence
based on 2 studies · most recent 2021
Regulatory Status
- Availability Status
- Research Only
- FDA Status
- Not Evaluated
Russian vascular peptide bioregulator (Lys-Glu-Asp) from Khavinson Institute. Developed for vascular endothelium health. Not FDA-approved. Not on any FDA list. Research chemical.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
2 sources cited · 2 weak
2 Reviews
Peptide Regulation of Gene Expression: A Systematic Review
Molecules · 2021
This systematic review documents the gene expression regulatory properties of short peptides including vesugen (Lys-Glu-Asp from vascular tissue), showing chromatin-binding activity and selective gene modulation in endothelial and vascular smooth muscle cells relevant to vascular aging and endothelial health.
Short Peptides in the Treatment of Age-Related Diseases
Stem Cell Reviews and Reports · 2020
This review summarizes the geroprotective properties of short regulatory peptides including vesugen, documenting effects on vascular tissue function, endothelial health, and longevity outcomes in animal models, with clinical data from the Khavinson program showing reduced vascular age-related pathology in treated cohorts.
Vesugen Side Effects & Safety Considerations
Research-use compound with limited human data. Evidence strength varies — see the Evidence section.
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Compare
VSVesugen
Certificates of Analysis
- Checkable — no result recordedPurity Peptides
Vesugen · Lot 260304VE203 · Mar 12, 2026 · View source COA
99.8%
Purity
PeptideBase reports these lab-published figures and does not itself test, endorse, or certify any product. Confirmed by lab results were matched against the issuing laboratory's own records — either the lab served the document, or its own hosted copy matches ours byte for byte. For every other result the badge states what is known about the lab: that it can be checked and no result is recorded yet, that it can't be checked, or that we have not reviewed it.
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
Frequently Asked Questions — Vesugen
Vesugen is a synthetic peptide classified as a Khavinson-class bioregulator targeted at vascular endothelial and smooth muscle tissue, investigated for cytoprotective and anti-aging effects on the vascular wall through proposed gene expression regulatory mechanisms acting on endothelial and smooth muscle cell populations. Like other Khavinson bioregulator peptides, vesugen is proposed to modulate gene expression in target vascular cells through interactions with chromatin regulatory elements and transcription factor binding sites, with effects proposed to support endothelial integrity and vascular wall homeostasis under conditions of aging-related cellular stress.
vascular repair, endothelial function, cardiovascular anti-aging, atherosclerosis reduction.
Research on Vesugen primarily documents effects related to vascular repair and endothelial function and cardiovascular anti-aging and atherosclerosis reduction. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
For Vesugen, its FDA status is not evaluated by the FDA, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
2 providers in the directory currently offer Vesugen.
Across 13 research vendors tracked on PeptideBase, Vesugen has a median price of about $2.75 per mg, typically ranging $2.51–$3.00 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.
How to get Vesugen
Market Pricing
13 vendorsPrice per mg varies by quantity, vendor type, and formulation. Research use only.
Data verified August 2026 · Vesugen price intelligence
Where to buy Vesugen
2 providersQuestions to ask your provider
Stay updated on Vesugen providers
New providers added weekly — delivered to your inbox.
Last updated
Keep exploring
Tools & Guides
Reconstitution Calculator
Convert vial size + BAC water volume into draw volume.
How to Reconstitute Peptides
Step-by-step guide: BAC water, vial prep, and storage after mixing.
Peptide Dosage Guide
Key factors that determine dosing in clinical practice.
Peptide Storage Guide
How to store lyophilized and reconstituted peptides.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Vesugen — Per-mg Price Benchmark. Retrieved September 11, 2026, from https://peptidebase.io/peptides/vesugen